Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterizing the tumor suppressor activity of FLCN in Birt-Hogg-Dubé syndrome cell models through transcriptomic and proteomic analysis

25 Mar 2025

Abstract excerpt

Abstract Birt-Hogg-Dubé syndrome (BHD) patients are uniquely susceptible to all renal tumor subtypes. However, the underlying mechanism of carcinogenesis is unclear. To study cancer development in BHD, we used human proximal kidney (HK2) cells and found that long-term folliculin ( FLCN ) knockdown was required to increase the tumorigenic potential of these cells, as evidenced by the formation of larger spheroids...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Microtubule and mitosis dynamics
Share to Renal and related cancers
Share to Renal cell carcinoma treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40133475
DOI: 10.1038/s41388-025-03325-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterizing the tumor suppressor activity of FLCN in Birt-Hogg-Dubé syndrome cell models through transcriptomic and proteomic analysisPMID 40133475Read ↗

Characterizing the tumor suppressor activity of FLCN in Birt-Hogg-Dubé syndrome through transcriptiomic and proteomic analysisSemantic proximity Read ↗

Clinical features, genetics and potential therapeutic approaches for Birt–Hogg–Dubé syndromeSemantic proximity Read ↗

Birt-Hogg-Dubé syndrome: Clinical and molecular aspects of recently identified kidney cancer syndrome.Semantic proximity Read ↗

Birt-Hogg-Dubé syndrome: from gene discovery to molecularly targeted therapies.Semantic proximity Read ↗

Birt–Hogg–Dubé syndrome is a novel ciliopathySemantic proximity Read ↗

Therapeutic Targeting the Loss of the Birt-Hogg-Dubé Suppressor GeneSemantic proximity Read ↗

Phosphoproteomic Analysis of FLCN Inactivation Highlights Differential Kinase Pathways and Regulatory TFEB PhosphoserinesSemantic proximity Read ↗

Renal tumour suppressor function of the Birt-Hogg-Dubé syndrome gene product folliculin.Semantic proximity Read ↗

Tumor suppressor FLCN inhibits tumorigenesis of a FLCN-null renal cancer cell line and regulates expression of key molecules in TGF-β signalingSemantic proximity Read ↗

Loss of FLCN-FNIP1/2 induces a non-canonical interferon response in human renal tubular epithelial cellsSemantic proximity Read ↗

FLCN: The causative gene for Birt-Hogg-Dubé syndrome.Semantic proximity Read ↗

Birt-Hogg-Dubé renal tumors are genetically distinct from other renal neoplasias and are associated with up-regulation of mitochondrial gene expressionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.